Abstract:A small‐molecular self‐assembly nano‐prodrug is developed to achieve the co‐delivery of gemcitabine, ferrocene, and nutlin‐3a for pancreatic ductal adenocarcinoma (PDAC) treatment. The nutlin‐3a not only induces high level of p53 expression for DNA‐damage‐induced apoptosis, but also sensitizes ferroptosis by the inhibition of ferroptosis resistance. The combination of apoptosis and ferroptosis can reduce the chemo‐resistance for enhanced PDAC therapeutics effect. Gemcitabine (GEM), as a first‐line chemotherapeutics for pancreatic ductal adenocarcinoma (PDAC) treatment, still faces several clinical challenges, restricted by instability in blood circulations, low tumor selectivity, and acquired nature characteristics of chemo‐resistance. To solve these challenges, the rational design of combination therapy with GEM and other therapy modalities is imperative. Herein, a small molecular self‐assembly nano‐prodrug is developed, which can achieve the co‐delivery of GEM, Ferrocene and nutlin‐3a on the achievement of GEM‐induced apoptosis with ferroptosis. In this nano‐prodrug, the disulfide linkage not only acts as a GSH‐responsive trigger but also plays an important role in self‐assembly behavior of nanoparticle that can load nutlin‐3a. Interestingly, nutlin‐3a plays an important role in both ferroptosis and apoptosis, one is effectively sensitized cells to ferroptosis by inhibiting cystine uptake, and the other is promoted apoptosis by elevating p53 expression. To further enhance the drug tumor accumulation and maintain stability in systemic circulations, this nano‐prodrug is then encapsulated into plectin1 receptor‐targeting phospholipid micelles (DSPE‐PEG‐PTP), which displays high selective tumor inhibition and good biosafety on different mice models, especially in orthotopic and patient‐derived xenograft (PDX) models. The findings provide new insights into the combination therapy of GEM with ferroptosis for reduced chemo‐resistance on PDAC treatment.

Gemcitabine and Pin1 siRNA co-delivery with fucoidan-coated nano-liposomes for therapy of pancreatic cancer

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Growth inhibition of pancreatic cancer by targeted delivery of gemcitabine via fucoidan-coated pH-sensitive liposomes

Membrane-camouflaged supramolecular nanoparticles for co-delivery of chemotherapeutic and molecular-targeted drugs with siRNA against patient-derived pancreatic carcinoma

Terminating the Criminal Collaboration in Pancreatic Cancer: Nanoparticle-based Synergistic Therapy for Overcoming Fibroblast-Induced Drug Resistance

Co-Delivery of Gemcitabine and Honokiol by Lipid Bilayer-Coated Mesoporous Silica Nanoparticles Enhances Pancreatic Cancer Therapy via Targeting Depletion of Tumor Stroma

Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement

Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer

Plectin-1-targeted recognition for enhancing comprehensive therapy in pancreatic ductal adenocarcinoma

A Self‐Assembly Combined Nano‐Prodrug to Overcome Gemcitabine Chemo‐Resistance of Pancreatic Tumors

Addressing Chemoresistance with a Lipid Gemcitabine Nanotherapeutic Strategy for Effective Treatment of Pancreatic Cancer

Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma

Epidermal Growth Factor Receptor Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib to Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation

A Tumor Microenvironment-Stimuli Responsive Nano-Prodrug for Overcoming Gemcitabine Chemoresistance by Co-Delivered Mirna-21 Modulator

Chemotherapy priming of the Pancreatic Tumor Microenvironment Promotes Delivery and Anti-Metastasis Efficacy of Intravenous Low-Molecular-Weight Heparin-Coated Lipid-siRNA Complex

Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer

Cancer cell membrane-modified Soluplus® micelles for gemcitabine delivery to pancreatic cancer using a prodrug approach

Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy.

IGF-1 Conjugated Sub-5 nm Ultrafine Iron Oxide Nanoparticle Enhances Targeted Drug Delivery and Efficacy of DNA Topoisomerase Inhibitor SN38 for Pancreatic Cancer: An in Vitro Study

Codelivery of Doxorubicin/PI3K Inhibitor Nanomicelle Linked with Phenylboronic Acid for Enhanced Cytotoxicity to Pancreatic Cancer

Nanomedicine Integrating the Lipidic Derivative of 5-Fluorouracil, Miriplatin and PD-L1 Sirna for Enhancing Tumor Therapy